I wonder if that would raise the FTC's hackles? Certainly REGN would complain bitterly about such a merger and resulting co-formulation. It speaks to so-called "tying" where a company attempts to extend a dominant position in one product so as to also encompass other products. I'm not aware of any examples of this happening in pharmaceuticals.
As noted in #msg-76571926, the technical problems of co-formulating Lucentis and Fovista may be more consequential than the legal/anti-competitive issues. I’m not aware of any cases of co-formulation involving a biologic (in this instance, a biologic and an aptamer). Do you know of any?
News 
Market Data 
Discover 
